| Literature DB >> 35290417 |
Xiao Xu1,2, Pamela R Soulos2,3, Jeph Herrin2,3, Shi-Yi Wang2,4, Craig Evan Pollack5,6,7, Brigid K Killelea8, Howard P Forman9, Cary P Gross2,3.
Abstract
BACKGROUND: Despite no proven benefit in clinical outcomes, perioperative magnetic resonance imaging (MRI) was rapidly adopted into breast cancer care in the 2000's, offering a prime opportunity for assessing factors influencing overutilization of unproven technology.Entities:
Mesh:
Year: 2022 PMID: 35290417 PMCID: PMC8923453 DOI: 10.1371/journal.pone.0265188
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Sample selection criteria.
SEER = Surveillance, Epidemiology, and End Results.
Characteristics of patients in the breast cancer sample (N = 26,886 patients).
| Characteristics | Overall | Perioperative MRI | ||
|---|---|---|---|---|
| N (%) | Yes | No | P Value | |
| N (%) | N (%) | |||
| Sample size | 26,886 | 5,302 | 21,584 | |
| Age | <0.001 | |||
| 66–69 | 5,839 (21.7) | 1,702 (32.1) | 4,137 (19.2) | |
| 70–74 | 6,688 (24.9) | 1,603 (30.2) | 5,085 (23.6) | |
| 75–79 | 6,344 (23.6) | 1,132 (21.4) | 5,212 (24.1) | |
| 80–84 | 4,878 (18.1) | 620 (11.7) | 4,258 (19.7) | |
| 85–94 | 3,317 (11.7) | 245 (4.6) | 2,892 (13.4) | |
| Race | <0.001 | |||
| White | 24,229 (90.1) | 4,890 (92.2) | 19,339 (89.6) | |
| Black | 1,725 (6.4) | 227 (4.3) | 1,498 (6.9) | |
| Other | 932 (3.5) | 185 (3.5) | 747 (3.5) | |
| Marital status | <0.001 | |||
| Married | 1,1894 (44.2) | 2,817 (53.1) | 9,077 (42.1) | |
| Unmarried | 13,929 (51.8) | 2,249 (42.4) | 11,680 (54.1) | |
| Unknown | 1,063 (4.0) | 236 (4.5) | 827 (3.8) | |
| Residence in a metropolitan area | <0.001 | |||
| Yes | 23,760 (88.4) | 4,868 (91.8) | 18,892 (87.5) | |
| No | 3,126 (11.6) | 434 (8.2) | 2,692 (12.5) | |
| Area-level median household income | <0.001 | |||
| <$33K | 4,649 (17.3) | 608 (11.5) | 4,041 (18.2) | |
| $33K-$40K | 3,889 (14.5) | 577 (10.9) | 3,312 (15.3) | |
| $40K-$50K | 5,955 (22.1) | 1,075 (20.3) | 4,880 (22.6) | |
| $50K-$63K | 5,685 (21.1) | 1,190 (22.4) | 4,495 (20.8) | |
| ≥$63K | 6,708 (24.9) | 1,850 (34.9) | 4,856 (22.5) | |
| Number of comorbidities | <0.001 | |||
| 0 | 14,737 (54.8) | 3,356 (63.3) | 11,381 (52.7) | |
| 1–2 | 9,516 (35.4) | 1,654 (31.2) | 7,862 (36.4) | |
| ≥3 | 2,633 (9.8) | 292 (5.5) | 2,341 (10.8) | |
| Stage | ||||
| I | 15,682 (58.3) | 3,138 (59.2) | 12,544 (58.1) | 0.02 |
| II | 8,603 (32.0) | 1,703 (32.1) | 6,900 (32.0) | |
| III | 2,601 (9.7) | 461 (8.7) | 2,140 (9.9) | |
| Grade | <0.001 | |||
| 1 | 6,825 (25.4) | 1,411 (26.6) | 5,414 (25.1) | |
| 2 | 11,801 (43.9) | 2,440 (46.0) | 9,361 (43.4) | |
| 3 | 6,808 (25.3) | 1,188 (22.4) | 5,620 (26.0) | |
| 4 | 217 (0.8) | 27 (0.5) | 190 (0.9) | |
| Missing | 1,235 (4.6) | 236 (4.5) | 999 (4.6) | |
| Tumor size, cm | <0.001 | |||
| <2 | 17,066 (63.5) | 3,523 (66.4) | 13,543 (62.7) | |
| 2–5 | 8,454 (31.4) | 1,512 (28.5) | 6,942 (32.2) | |
| >5 | 1,183 (4.4) | 225 (4.2) | 958 (4.4) | |
| Missing | 183 (0.7) | 42 (0.8) | 141 (0.7) | |
| Node positive | 0.42 | |||
| No | 20,404 (75.9) | 4,001 (75.5) | 16,403 (76.0) | |
| Yes | 6,482 (24.1) | 1,301 (24.5) | 5,181 (24.0) | |
| Hormone receptor status | <0.001 | |||
| Negative | 3,654 (13.6) | 670 (12.6) | 2,984 (13.8) | |
| Positive | 21,878 (81.4) | 4,450 (83.9) | 17,428 (80.7) | |
| Unknown | 1,354 (5.0) | 182 (3.4) | 1,172 (5.4) | |
| Tumor laterality | 0.19 | |||
| Right-sided | 13,234 (49.2) | 2,653 (50.0) | 10,581 (49.0) | |
| Left-sided | 13,652 (50.8) | 2,649 (50.0) | 11,003 (51.0) | |
MRI = magnetic resonance imaging.
a Fewer than 11 patients with unknown area level median household income were included in the middle category ($40K-$50K) due to privacy concerns.
Characteristics of physician patient-sharing networks, overall and across the distinct trajectory groups (N = 147 physician patient-sharing networks).
| Network Characteristics | Overall | Distinct Adoption Trajectory | |||
|---|---|---|---|---|---|
| Low Adoption | Medium Adoption | High Adoption | Kendall’s Tau-b Rank Correlation | ||
| (N = 147) | (N = 85) | (N = 48) | (N = 14) | ||
| Patient composition | |||||
| Number of breast cancer patients | 145 (99, 226) | 119 (94, 216) | 156.5 (110.5, 270) | 137.5 (93, 180) | 0.09 (p = 0.16) |
| Area-level median household income | 49,972 (41,644, 60,254) | 46,733 (39,197, 57,138) | 54,519 (45,813, 66,168) | 59,287 (49,972, 69,767) |
|
| Proportion of breast cancer patients who | 2.6 (0.7, 7.0) | 4.4 (0.9, 8.7) | 1.8 (0.7, 5.0) | 1.3 (0.0, 3.8) |
|
| Proportion of breast cancer patients residing in a metropolitan area (%) | 98.9 (82.5, 100.0) | 98.3 (81.7, 100.0) | 99.7 (82.3, 100.0) | 100.0 (95.2, 100.0) | 0.09 (p = 0.21) |
| Proportion of breast cancer patients who had a PCP visit in the past year (%) | 93.8 (92.2, 95.3) | 93.6 (92.2, 95.1) | 93.9 (91.7, 95.2) | 95.2 (93.3, 96.2) | 0.07 (p = 0.31) |
| Physician composition | |||||
| Number of physicians | 133 (90, 204) | 116 (87, 200) | 142 (103, 228) | 133 (82, 183) | 0.04 (p = 0.51) |
| Proportion of physicians who were | |||||
| Surgeons (%) | 10.7 (9.1, 12.4) | 11.0 (9.2, 12.4) | 10.5 (9.1, 12.4) | 10.0 (8.2, 12.2) | -0.06 (p = 0.40) |
| Medical oncologists (%) | 7.1 (5.7, 8.8) | 6.7 (5.3, 8.5) | 7.8 (6.3, 9.2) | 8.2 (6.2, 12.8) |
|
| Radiation oncologists (%) | 4.3 (3.1, 6.3) | 4.1 (2.9, 6.1) | 4.1 (3.1, 5.9) | 7.2 (5.7, 9.9) |
|
| Radiologists (%) | 23.2 (18.6, 27.8) | 22.8 (18.2, 26.3) | 24.1 (20.2, 28.3) | 24.8 (18.0, 31.6) | 0.09 (p = 0.16) |
| Primary care physicians (%) | 53.6 (47.3, 59.0) | 55.5 (48.0, 59.5) | 52.7 (46.9, 57.7) | 48.2 (43.6, 54.4) |
|
PCP = primary care physician.
Data reported as median (interquartile range). Bold font indicates correlation coefficients that are statistically significant.
Fig 2Distinct trajectories of adopting perioperative MRI among physician patient-sharing networks.
MRI = magnetic resonance imaging. Rate of perioperative MRI use reflects risk-adjusted rate for each physician patient-sharing network in each time-period after accounting for differences in patient tumor characteristics and other clinical risk factors. Solid lines reflect mean risk-adjusted rate among physician patient-sharing networks in each trajectory. Dotted lines reflect trajectories predicted by the growth mixture model, with error bars reflecting 95% confidence intervals.
Changes in the proportion of surgeons using perioperative MRI and intensity of utilization over time across the distinct trajectories (N = 1,969 surgeons).
| Time-Period | Low Adoption (N = 1,163) | Medium Adoption (N = 670) | High Adoption (N = 136) |
|---|---|---|---|
| Proportion with any use: Whether a surgeon had any patients using perioperative MRI | |||
| 2004–2005 | 11.9% | 30.5% | 58.8% |
| 2006–2007 | 25.1% | 49.0% | 74.0% |
| 2008–2009 | 39.2% | 69.2% | 83.5% |
| Increase between 2004–2005 and 2008–2009 | 27.3 percentage points | 38.7 percentage points | 24.7 percentage points |
| Mean intensity of use among early non-users: What proportion of a surgeon’s patients used perioperative MRI (if the surgeon did not use perioperative MRI at baseline) | |||
| 2004–2005 | 0% | 0% | 0% |
| 2006–2007 | 5.7% | 13.8% | 38.4% |
| 2008–2009 | 10.2% | 34.3% | 55.8% |
| Increase between 2004–2005 and 2008–2009 | 10.2 percentage points | 34.3 percentage points | 55.8 percentage points |
| Mean intensity of use among early users: What proportion of a surgeon’s patients used perioperative MRI (if the surgeon used perioperative MRI at baseline) | |||
| 2004–2005 | 22.8% | 27.1% | 46.1% |
| 2006–2007 | 19.9% | 32.8% | 52.0% |
| 2008–2009 | 23.0% | 47.1% | 69.7% |
| Increase between 2004–2005 and 2008–2009 | 0.2 percentage points | 20.0 percentage points | 23.6 percentage points |
MRI = magnetic resonance imaging.
Fig 3Risk-adjusted proportion of patients using mastectomy over time, by the distinct trajectories of MRI adoption.
MRI = magnetic resonance imaging. Error bars reflect 95% confidence intervals.